May 9th 2024
Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
FDA Gives Investigational Drug Fast Track Designation for Advanced Breast Cancer Subtype
January 13th 2023The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation
A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.
Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease
Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.
Study Results Show Shorter Radiation for Breast Cancer is ‘Worthy of Further Study’
January 11th 2023An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.
Viability of Breast Conservation Therapy Gives Patients ‘More of a Choice,’ Says Expert
January 8th 2023Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.
Shorter Radiation After Mastectomy Could Improve Access for Patients With Breast Cancer
January 7th 2023If feasible, hypofractionated radiation—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy would provide more patients with breast cancer a tissue-sparing option, according to an expert from the Mayo Clinic.
Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease
Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.
HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib
Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease
Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
Patient Case 2: HER2+ Breast Cancer With CNS Metastases
Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.